Cassava Sciences, Inc. (SAVA)

Market Cap	104.35M
Revenue (ttm)	n/a
Net Income (ttm)	-72.79M
Shares Out	48.31M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	628,568
Open	2.180
Previous Close	2.190
Day's Range	2.130 - 2.210
52-Week Range	1.150 - 42.200
Beta	-2.05
Analysts	Buy
Price Target	54.50 (+2,423.15%)
Earnings Date	Aug 7, 2025

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: SAVA
• Website: https://www.cassavasciences.com

Analyst Summary

According to 2 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price target is $54.5, which is an increase of 2,423.15% from the latest price.

Price Target

$54.5

(2,423.15% upside)

Analyst Consensus: Buy